moxifloxacin has been researched along with doxazosin in 4 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (doxazosin) | Trials (doxazosin) | Recent Studies (post-2010) (doxazosin) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 1,372 | 439 | 283 |
| Protein | Taxonomy | moxifloxacin (IC50) | doxazosin (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.544 | |
| Interstitial collagenase | Homo sapiens (human) | 5.749 | |
| Beta-2 adrenergic receptor | Homo sapiens (human) | 2.748 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 2.2155 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.0034 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.544 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 2.688 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.368 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0007 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 0.188 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4022 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 2.2155 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Sen, S; Sinha, N | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for moxifloxacin and doxazosin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for moxifloxacin and doxazosin
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |